

Jaguar Animal Health, Inc.
Form 8-K
June 09, 2016

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): **June 8, 2016**

Jaguar Animal Health, Inc.

(Exact name of registrant as specified in its charter)

Delaware

(State or jurisdiction of incorporation or organization)

001-36714

(Commission File Number)

46-2956775

(I.R.S. Employer Identification Number)

Edgar Filing: Jaguar Animal Health, Inc. - Form 8-K

201 Mission Street, Suite 2375, San Francisco, CA 94105

(Address of principal executive offices (Zip Code))

Registrant's telephone number: **(415) 371-8300**

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c))

Item 1.01

Entry into a Material Definitive Agreement.

Purchase Agreement and Registration Rights Agreement with Aspire Capital

On June 8, 2016, Jaguar Animal Health, Inc. (the **Company**), entered into a common stock purchase agreement (the **Purchase Agreement**) with Aspire Capital Fund, LLC, an Illinois limited liability company (**Aspire Capital**) which provides that, upon the terms and subject to the conditions and limitations set forth therein, Aspire Capital is committed to purchase up to an aggregate of \$15.0 million of shares of the **Company**'s common stock over the 30-month term of the **Purchase Agreement**. Upon execution of the **Purchase Agreement**, the **Company** agreed to sell to Aspire Capital 222,222 shares of common stock at \$2.25 per share for proceeds of \$500,000. Concurrently with entering into the **Purchase Agreement**, the **Company** also entered into a registration rights agreement with Aspire Capital (the **Registration Rights Agreement**), in which the **Company** agreed to file one or more registration statements, as permissible and necessary to register under the Securities Act of 1933, as amended (the **Securities Act**), registering the sale of the shares of the **Company**'s common stock that have been and may be issued to Aspire Capital under the **Purchase Agreement**.

Under the **Purchase Agreement**, after the Securities and Exchange Commission (the **SEC**) has declared effective the registration statement referred to above, on any trading day selected by the **Company**, the **Company** has the right, in its sole discretion, to present Aspire Capital with a purchase notice (each, a **Purchase Notice**), directing Aspire Capital (as principal) to purchase up to 100,000 shares of the **Company**'s common stock per business day, up to \$15.0 million of the **Company**'s common stock in the aggregate at a per share price (the **Purchase Price**) equal to the lesser of:

- the lowest sale price of the **Company**'s common stock on the purchase date; or
- the arithmetic average of the three (3) lowest closing sale prices for the **Company**'s common stock during the ten (10) consecutive trading days ending on the trading day immediately preceding the purchase date.

In addition, on any date on which the **Company** submits a **Purchase Notice** to Aspire Capital in an amount equal to 100,000 shares, the **Company** also has the right, in its sole discretion, to present Aspire Capital with a volume-weighted average price purchase notice (each, a **VWAP Purchase Notice**) directing Aspire Capital to purchase an amount of stock equal to up to 30% of the aggregate shares of the **Company**'s common stock traded on its principal market on the next trading day (the **VWAP Purchase Date**), subject to a maximum number of shares the **Company** may determine. The purchase price per share pursuant to such **VWAP Purchase Notice** is generally 97% of the volume-weighted average price for the **Company**'s common stock traded on its principal market on the **VWAP Purchase Date**.

The **Purchase Price** will be adjusted for any reorganization, recapitalization, non-cash dividend, stock split, or other similar transaction occurring during the period(s) used to compute the **Purchase Price**. The **Company** may deliver multiple **Purchase Notices** and **VWAP Purchase Notices** to Aspire Capital from time to time during the term of the **Purchase Agreement**, so long as the most recent purchase has been completed.

The **Purchase Agreement** provides that the **Company** and Aspire Capital shall not effect any sales under the **Purchase Agreement** on any purchase date where the closing sale price of the **Company**'s common stock is less than \$0.50. There are no trading volume requirements or

Edgar Filing: Jaguar Animal Health, Inc. - Form 8-K

restrictions under the Purchase Agreement, and the Company will control the timing and amount of sales of the Company's common stock to Aspire Capital. Aspire Capital has no right to require any sales by the Company, but is obligated to make purchases from the Company as directed by the Company in accordance with the

Purchase Agreement. There are no limitations on use of proceeds, financial or business covenants, restrictions on future fundings, rights of first refusal, participation rights, penalties or liquidated damages in the Purchase Agreement. In consideration for entering into the Purchase Agreement, concurrently with the execution of the Purchase Agreement, the Company issued to Aspire Capital 456,667 shares of the Company's common stock (the Commitment Shares). The Purchase Agreement may be terminated by the Company at any time, at its discretion, without any cost to the Company. Aspire Capital has agreed that neither it nor any of its agents, representatives and affiliates shall engage in any direct or indirect short-selling or hedging of the Company's common stock during any time prior to the termination of the Purchase Agreement. Any proceeds that the Company receives under the Purchase Agreement are expected to be used for working capital, general corporate purposes and business development activities.

The foregoing is a summary description of certain terms of the Purchase Agreement and the Registration Rights Agreement and, by its nature, is incomplete. Copies of the Purchase Agreement and Registration Rights Agreement are filed herewith as Exhibits 10.1 and 4.1, respectively, to this Current Report on Form 8-K and are incorporated herein by reference. All readers are encouraged to read the entire text of the Purchase Agreement and the Registration Rights Agreement.

The issuance of the Commitment Shares and all other shares of common stock that may be issued from time to time to Aspire Capital under the Purchase Agreement is exempt from registration under the Securities Act, pursuant to the exemption for transactions by an issuer not involving any public offering under Section 4(a)(2) of the Securities Act.

This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements related to the potential future sale of shares of the Company's common stock and price for such sales under the Purchase Agreement. The words may, will, could, would, should, expect, intend, plan, and believe, estimate, predict, project, potential, continue, ongoing and similar expressions are intended to identify forward-looking statements although not all forward-looking statements contain these identifying words. While the Company believes its plans, intentions and expectations reflected in those forward-looking statements are reasonable, these plans, intentions or expectations may not be achieved. The Company's actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements. For information about the factors that could cause such differences, please refer to the Company's Annual Report on Form 10-K for the year ended December 31, 2015, including the information discussed under the captions Item 1 Business, Item 1A. Risk Factors and Item 7 Management's Discussion and Analysis of Financial Condition and Results of Operations, as well as the Company's various other filings with the SEC. Given these uncertainties, you should not place undue reliance on these forward-looking statements. The Company assumes no obligation to update any forward-looking statement.

Item 3.02 Unregistered Sales of Equity Securities.

The information contained above in Item 1.01 is hereby incorporated by reference into this Item 3.02 in its entirety.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number	Description
4.1	Registration Rights Agreement, dated June 8, 2016, between Jaguar Animal Health, Inc. and Aspire Capital Fund, LLC *
10.1	Common Stock Purchase Agreement, dated June 8, 2016 between Jaguar Animal Health, Inc. and Aspire Capital Fund, LLC *

*Filed herewith.

Signature(s)

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

JAGUAR ANIMAL HEALTH, INC.

Date: June 9, 2016

By:

Name:

Title:

/s/ Karen S. Wright

Karen S. Wright

Chief Financial Officer